An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Wei Shi, Guangdong General Hospital

ClinicalTrials.gov Identifier:

NCT01502579

First received: December 29, 2011

Last updated: August 27, 2013

Last verified: August 2013

History of Changes

Purpose

The pathological variants of IgA nephropathy identified by the Oxford classification may be related to the clinical data at presentation and follow-up, including proteinuria and renal function. This study is aimed to identify the potential relationship between pathological variants and clinical data in IgA nephropathy.

Condition
IgA Nephropathy


Study Type:	Observational
Study Design:	Time Perspective: Prospective
Official Title:	An Observational Study of the Relationship Between Pathological Variants and Clinical Data at Presentation and Follow-up in IgA Nephropathy

Resource links provided by NLM:

MedlinePlus related topics: Kidney Diseases

Drug Information available for: Immunoglobulin A

Genetic and Rare Diseases Information Center resources: IgA Nephropathy Glomerulonephritis

U.S. FDA Resources

Further study details as provided by Wei Shi, Guangdong General Hospital:

Primary Outcome Measures:

glomerular filtration rate decline or end-stage renal disease or doubling of serum creatinine [ Time Frame: after the biopsy ]


Enrollment:	603
Study Start Date:	September 2011
Study Completion Date:	August 2013
Primary Completion Date:	August 2013 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	18 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

The population from which the cohort will be selected is these who have received renal biopsy in Guangdong General Hospital

Criteria

Inclusion Criteria:

biopsy-proven IgA nephropathy;

Exclusion Criteria:

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01502579

Locations


China, Guangdong
Guangdong General Hospital
Guangzhou, Guangdong, China, 510080

Sponsors and Collaborators

Guangdong General Hospital

Investigators


Principal Investigator:	Wei Shi, MD,PhD	Guangdong General Hospital

More Information


Responsible Party:	Wei Shi, Professor, Guangdong General Hospital
ClinicalTrials.gov Identifier:	NCT01502579 History of Changes
Other Study ID Numbers:	GGH201106
Study First Received:	December 29, 2011
Last Updated:	August 27, 2013

Keywords provided by Wei Shi, Guangdong General Hospital:


IgA nephropathy

Additional relevant MeSH terms:


Kidney Diseases Glomerulonephritis, IGA Urologic Diseases Glomerulonephritis	Nephritis Autoimmune Diseases Immune System Diseases

ClinicalTrials.gov processed this record on June 23, 2017

To Top